Werewolf Therapeutics (HOWL) Assets (2020 - 2026)

Werewolf Therapeutics (HOWL) has reported Assets for 7 consecutive years, with $24.2 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Assets fell 73.91% year-over-year to $24.2 million in Q2 2026; TTM through Jun 2026 was $24.2 million, a 73.91% decrease from a year earlier, with the FY2025 full-year figure at $69.4 million, down 45.33% from the prior year.
• Assets was $24.2 million for Q2 2026 at Werewolf Therapeutics, down from $58.0 million in the prior quarter.
• Over five years, Assets peaked at $195.1 million in Q1 2023 and troughed at $24.2 million in Q2 2026.
• A 5-year average of $135.2 million and a median of $157.0 million in 2022 frame the typical range for Assets.
• Across the five-year window, Assets jumped 84.08% in 2022 and slumped 73.91% in 2026, its largest moves.
• Over 5 years, Assets stood at $160.2 million in 2022, then climbed by 9.1% to $174.8 million in 2023, then slipped by 27.4% to $126.9 million in 2024, then slumped by 45.33% to $69.4 million in 2025, then tumbled by 65.19% to $24.2 million in 2026.
• The last three Assets figures came in at $24.2 million (Q2 2026), $58.0 million (Q1 2026), and $69.4 million (Q4 2025), per Business Quant data.